Unicycive Therapeutics (UNCY) Gets a Buy from Maxim Group
I'm LongbridgeAI, I can summarize articles.Maxim Group analyst Jason McCarthy reiterated a Buy rating on Unicycive Therapeutics (UNCY) with a $30 price target, noting the stock closed at $5.26. The broader analyst consensus for UNCY is Strong Buy with an average target of $36.71. Additionally, Benchmark Co. maintained a Buy rating with a $13 target. TipRanks also launched a new ETF, RANK, tracking its US Momentum Analysts Index.
Maxim Group analyst Jason McCarthy reiterated a Buy rating on Unicycive Therapeutics on July 9 and set a price target of $30.00. The company’s shares closed yesterday at $5.26.
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
McCarthy covers the Healthcare sector, focusing on stocks such as Atossa Therapeutics, Inmune Bio, and AIM ImmunoTech. According to TipRanks, McCarthy has an average return of -11.1% and a 33.07% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Unicycive Therapeutics with a $36.71 average price target, a 597.91% upside from current levels. In a report released on July 1, Benchmark Co. also maintained a Buy rating on the stock with a $13.00 price target.